Intensive blood pressure control did not prevent major CV events more than standard control in type 2 diabetes
Authors: C. Raina Elley
Journal: Annals of Internal Medicine (2010)

ACP Journal Club20 July 2010Intensive blood pressure control did not prevent major CV events more than standard control in type 2 diabetesC. Raina Elley, MBChB, PhD, Vanessa Selak, MBChB, MPHC. Raina Elley, MBChB, PhDUniversity of Auckland, Auckland, New Zealand (C.R.E., V.S.)Search for more papers by this author, Vanessa Selak, MBChB, MPHUniversity of Auckland, Auckland, New Zealand (C.R.E., V.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-2-201007200-02004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. https://pubmed.ncbi.nlm.nih.gov/20228401Clinical Impact RatingsGIM/FP/GP: Endocrinology: References1 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. [PMID: 19454737] Google Scholar2 Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. [PMID: 12829555] Google Scholar3 Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] Google Scholar4 US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404. [PMID: 19293072] Google Scholar5 Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007;154:943-53. [PMID: 17967602] Google Scholar6 Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61. [PMID: 16310551] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Auckland, Auckland, New Zealand (C.R.E., V.S.)This article was published at Annals.org on 6 July 2010. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFenofibrate plus simvastatin did not prevent major CV events more than simvastatin alone in type 2 diabetes C. Raina Elley and Vanessa Selak Metrics 20 July 2010Volume 153, Issue 2Page: JC1-4KeywordsAntihypertensive drug therapyBlood pressureCardiovascular therapyCreatinineDrugsMyocardial infarctionStatinsStrokeType 2 diabetes ePublished: 20 July 2010 Issue Published: 20 July 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...